Qinchuan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qinchuan Wang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Wenjing Li
Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
5 shared publications- Xifeng Wu
Center of Clinical Big Data and Analytics of the Second Affiliated Hospital, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China
4 shared publications Jichun Zhou
Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publicationsJida Chen
Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, China
3 shared publicationsLin Chen
Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
3 shared publicationsLinbo Wang
Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in BMC Cancer
Soluble immune checkpoints proteins are significantly associated with the susceptibility of renal cell cancer, a case–control study
- 21 September 2026
- Published by Springer Nature in BMC Cancer
Open AccessSoluble immune checkpoints proteins are significantly associated with the susceptibility of renal cell cancer, a case–control study
- Open Access
- 9 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1307
Stage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities
Mucins are a class of highly glycosylated macromolecules that constitute a cornerstone of the gastrointestinal mucosal barrier and play multiple essential roles in maintaining tissue homeostasis. During the progression from normal gastric mucosa through precancerous lesions to gastric cancer and metastasis, the expression profiles, glycosylation patterns, and spatial distribution of mucins undergo systematic and programmatic alterations, a process referred to as “mucin reprogramming.” Recent studies have revealed that this reprogramming is by no means a passive bystander phenomenon accompanying tumorigenesis; rather, it is a central biological event that actively drives malignant transformation, shapes an immunosuppressive microenvironment, and influences therapeutic response. This article aims to systematically delineate the dynamic landscape of mucin expression changes during gastric cancer progression, to provide an in-depth analysis of the underlying molecular mechanisms, and to focus on its clinical value and translational potential in the early diagnosis, molecular classification, prognostic assessment, and targeted therapy of gastric cancer. In addition, this review also discusses recent applications of artificial intelligence in the precise identification of mucin phenotypic features. By integrating the latest research advances, this review seeks to provide new perspectives and a theoretical basis for a deeper understanding of the mechanisms of mucin reprogramming during gastric cancer progression and for the development of novel diagnostic and therapeutic strategies.
- 9 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1307
Open AccessStage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities
Mucins are a class of highly glycosylated macromolecules that constitute a cornerstone of the gastrointestinal mucosal barrier and play multiple essential roles in maintaining tissue homeostasis. During the progression from normal gastric mucosa through precancerous lesions to gastric cancer and metastasis, the expression profiles, glycosylation patterns, and spatial distribution of mucins undergo systematic and programmatic alterations, a process referred to as “mucin reprogramming.” Recent studies have revealed that this reprogramming is by no means a passive bystander phenomenon accompanying tumorigenesis; rather, it is a central biological event that actively drives malignant transformation, shapes an immunosuppressive microenvironment, and influences therapeutic response. This article aims to systematically delineate the dynamic landscape of mucin expression changes during gastric cancer progression, to provide an in-depth analysis of the underlying molecular mechanisms, and to focus on its clinical value and translational potential in the early diagnosis, molecular classification, prognostic assessment, and targeted therapy of gastric cancer. In addition, this review also discusses recent applications of artificial intelligence in the precise identification of mucin phenotypic features. By integrating the latest research advances, this review seeks to provide new perspectives and a theoretical basis for a deeper understanding of the mechanisms of mucin reprogramming during gastric cancer progression and for the development of novel diagnostic and therapeutic strategies.
- Open Access
- 18 May 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Artificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives
Neoadjuvant chemotherapy (NAC) is a critical therapeutic strategy for locally advanced breast cancer; however, its clinical utility is constrained by tumor
- 18 May 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Open AccessArtificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives
Neoadjuvant chemotherapy (NAC) is a critical therapeutic strategy for locally advanced breast cancer; however, its clinical utility is constrained by tumor
- Open Access
- 21 December 2025
- Published by Association for Computing Machinery (ACM)
- p. 175-180
Evaluating the Challenges of LLMs in Real-world Medical Follow-up: A Comparative Study and An Optimized Framework
- 21 December 2025
- Published by Association for Computing Machinery (ACM)
- p. 175-180
Open AccessEvaluating the Challenges of LLMs in Real-world Medical Follow-up: A Comparative Study and An Optimized Framework
- Open Access
- 29 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Large language models could be applied in personalized out-of-hospital management for breast cancer: a prospective randomized single blind study
Personalized out-of-hospital management could significantly improve quality of life of breast cancer patients. We aimed to evaluate the accuracy, effectiveness, safety, personalization and emotional care of Large Language Models (LLMs) in the out-of-hospital management of breast cancer. We established a data cleaning and classification pipeline to summarize three major scenarios of out-of-hospital management. Authentic electronic health record (EHR) datasets for data collection were generated using 10 patients with ID information masked from Breast Cancer Database in Affiliated Sir Run Run Shaw Hospital, Zhejiang University. Then we matched the EHR datasets with three out-of-hospital management scenarios as 100 virtual patients (VPs) for LLMs to perform the conversation generation using GPT-o3 and DeepSeek-R1. Further, we incorporated four human specialists to rate the responses of LLMs in five dimensions using Likert scale. As of April 1, 2025, the 4 evaluator specialists rated the conversations of LLMs and 100 VPs. The results demonstrate that both DS-R1and GPT-o3 performed well, with scores primarily concentrated at 3 and 4 points. We revealed statistically significant differences between DS-R1and GPT-o3 in accuracy, personalization, and emotional care (P < 0.01). However, the P-values for effectiveness and safety were 0.231 and 0.086. Furthermore, DS-R1generated more tokens (approximately 1.8 times) in identical time with less economic cost, and it also had shorter response time than GPT-o3. GPT-o3 and DS-R1 demonstrated personalized, empathetic, and accurate performance in the out-of-hospital management for breast cancer patients. DS-R1 had better overall performance than GPT-o3, especially in personalization, emotional care and accuracy. More research is warranted in the development specific knowledge embedding LLMs to reduce the detractors like hallucinatory or verbose responses.
- 29 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessLarge language models could be applied in personalized out-of-hospital management for breast cancer: a prospective randomized single blind study
Personalized out-of-hospital management could significantly improve quality of life of breast cancer patients. We aimed to evaluate the accuracy, effectiveness, safety, personalization and emotional care of Large Language Models (LLMs) in the out-of-hospital management of breast cancer. We established a data cleaning and classification pipeline to summarize three major scenarios of out-of-hospital management. Authentic electronic health record (EHR) datasets for data collection were generated using 10 patients with ID information masked from Breast Cancer Database in Affiliated Sir Run Run Shaw Hospital, Zhejiang University. Then we matched the EHR datasets with three out-of-hospital management scenarios as 100 virtual patients (VPs) for LLMs to perform the conversation generation using GPT-o3 and DeepSeek-R1. Further, we incorporated four human specialists to rate the responses of LLMs in five dimensions using Likert scale. As of April 1, 2025, the 4 evaluator specialists rated the conversations of LLMs and 100 VPs. The results demonstrate that both DS-R1and GPT-o3 performed well, with scores primarily concentrated at 3 and 4 points. We revealed statistically significant differences between DS-R1and GPT-o3 in accuracy, personalization, and emotional care (P < 0.01). However, the P-values for effectiveness and safety were 0.231 and 0.086. Furthermore, DS-R1generated more tokens (approximately 1.8 times) in identical time with less economic cost, and it also had shorter response time than GPT-o3. GPT-o3 and DS-R1 demonstrated personalized, empathetic, and accurate performance in the out-of-hospital management for breast cancer patients. DS-R1 had better overall performance than GPT-o3, especially in personalization, emotional care and accuracy. More research is warranted in the development specific knowledge embedding LLMs to reduce the detractors like hallucinatory or verbose responses.
- Open Access
- 8 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (11) , 8270-8283
Artificial Intelligence in digital pathology of breast cancer, new era of practice?
Breast cancer is the most common cancers among women worldwide. Early diagnosis and personalized medicine are crucial for the treatment of breast cancer. With the development of computer science and the emergence of whole slide imaging technology, artificial intelligence (AI) is having a surprisingly positive impact on the field of pathology, including breast pathology. The deployment of AI provides powerful tools for research in digital pathology and provides potential solutions in precision medicine in breast cancer. In this review, we systematically reviewed the applications of AI in digital pathology of breast cancer, including the identification of histological features, such as tumor-infiltrating lymphocytes, and the evaluation of classical biomarkers, such as human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor. We also introduce the combined use of AI with multi-omics data in outcome prediction and treatment in breast cancer, and outline the evolution of AI methods applied in digital pathology. Collectively, the robustly evolving AI technologies would profoundly impact the precision pathology and medicine in breast cancer.
- 8 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (11) , 8270-8283
Open AccessArtificial Intelligence in digital pathology of breast cancer, new era of practice?
Breast cancer is the most common cancers among women worldwide. Early diagnosis and personalized medicine are crucial for the treatment of breast cancer. With the development of computer science and the emergence of whole slide imaging technology, artificial intelligence (AI) is having a surprisingly positive impact on the field of pathology, including breast pathology. The deployment of AI provides powerful tools for research in digital pathology and provides potential solutions in precision medicine in breast cancer. In this review, we systematically reviewed the applications of AI in digital pathology of breast cancer, including the identification of histological features, such as tumor-infiltrating lymphocytes, and the evaluation of classical biomarkers, such as human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor. We also introduce the combined use of AI with multi-omics data in outcome prediction and treatment in breast cancer, and outline the evolution of AI methods applied in digital pathology. Collectively, the robustly evolving AI technologies would profoundly impact the precision pathology and medicine in breast cancer.
- Open Access
- 1 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-11
Clinical characteristics and predictive models of HER2-low breast cancer patients who only received adjuvant chemotherapy: a real-world retrospective multicenter study
HER2-low positivity is reported to play substantial role in neoadjuvant chemotherapy for breast cancer, but its role in adjuvant chemotherapy remains unclear. We aim to explore the role of HER2-low positivity in the breast cancer patients who only received adjuvant chemotherapy. We evaluated 3214 patients from SRRSH Hospital and 16,273 patients from CHLP Hospital. All the patients were diagnosed as primary breast cancer who only received adjuvant chemotherapy. HER2-status was defined according to ASCO/CAP guidelines. Multivariable Cox models and machine learning models were applied in the analysis of overall survival. A total of 1009 HER2-zero, 1399 HER2-low and 806 HER2-positive patients were included in SRRSH cohort, while there were 5662 HER2-zero, 6471 HER2-low and 4140 HER2-positive patients in CHLP cohort. HER2-low patients showed significant better OS and reduced death risk compare to HER2-zero patients in both SRRSH (log-rank p = 0.033, HR = 0.62, 95% CI 0.39–0.97, p = 0.037) and CHLP cohort (log-rank p < 0.001, HR = 0.63, 95% CI 0.55–0.73, p < 0.001). In subgroup analysis, HER2-low patients had significantly reduced risk of death compare to HER2-zero patients in hormonal receptor-positive subset in both cohorts, but not in hormonal receptor-negative subset. MLP model demonstrated the best performance among all the predictive models in both cohorts. Our study indicated that HER2-low patients had better survival compare to HER2-zero patients in adjuvant chemotherapy only setting. We emphasized the significance of HER2 status in adjuvant setting in BC, implying more precise diagnostic and therapeutic strategies in future.
- 1 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-11
Open AccessClinical characteristics and predictive models of HER2-low breast cancer patients who only received adjuvant chemotherapy: a real-world retrospective multicenter study
HER2-low positivity is reported to play substantial role in neoadjuvant chemotherapy for breast cancer, but its role in adjuvant chemotherapy remains unclear. We aim to explore the role of HER2-low positivity in the breast cancer patients who only received adjuvant chemotherapy. We evaluated 3214 patients from SRRSH Hospital and 16,273 patients from CHLP Hospital. All the patients were diagnosed as primary breast cancer who only received adjuvant chemotherapy. HER2-status was defined according to ASCO/CAP guidelines. Multivariable Cox models and machine learning models were applied in the analysis of overall survival. A total of 1009 HER2-zero, 1399 HER2-low and 806 HER2-positive patients were included in SRRSH cohort, while there were 5662 HER2-zero, 6471 HER2-low and 4140 HER2-positive patients in CHLP cohort. HER2-low patients showed significant better OS and reduced death risk compare to HER2-zero patients in both SRRSH (log-rank p = 0.033, HR = 0.62, 95% CI 0.39–0.97, p = 0.037) and CHLP cohort (log-rank p < 0.001, HR = 0.63, 95% CI 0.55–0.73, p < 0.001). In subgroup analysis, HER2-low patients had significantly reduced risk of death compare to HER2-zero patients in hormonal receptor-positive subset in both cohorts, but not in hormonal receptor-negative subset. MLP model demonstrated the best performance among all the predictive models in both cohorts. Our study indicated that HER2-low patients had better survival compare to HER2-zero patients in adjuvant chemotherapy only setting. We emphasized the significance of HER2 status in adjuvant setting in BC, implying more precise diagnostic and therapeutic strategies in future.
- Open Access
- 2 September 2024
- Published by Springer Nature in Biomarker Research
- Vol. 12 (1) , 1-20
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Immunotherapy has emerged as a pivotal modality in cancer treatment, with immune checkpoint inhibitors effectively combating malignancies by impeding crucial pathways within the immune system and stimulating patients’ immune responses. Soluble forms of immune checkpoints exhibit a remarkable diversity and can be readily tracked in circulation, holding immense potential as biomarkers for cancer treatment. An increasing number of studies focused on soluble immune checkpoints in cancer have emerged thanks to technological advancements. In this systematic review, we comprehensively summarized the recent studies on soluble immune checkpoints in human cancer risk prediction, outcome prediction, therapeutic applications, and potential molecular mechanisms, which demonstrated the promising future of soluble immune checkpoints in clinical applications. The clinical relevance of soluble immune checkpoints has been recognized in multiple cancers, yet the therapeutic applications and mechanisms remain obscure. Interpreting the impacts and mechanisms of soluble immune checkpoints could shed a light on the novel strategies of cancer screening, treatments, and outcome prediction.
- 2 September 2024
- Published by Springer Nature in Biomarker Research
- Vol. 12 (1) , 1-20
Open AccessSoluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Immunotherapy has emerged as a pivotal modality in cancer treatment, with immune checkpoint inhibitors effectively combating malignancies by impeding crucial pathways within the immune system and stimulating patients’ immune responses. Soluble forms of immune checkpoints exhibit a remarkable diversity and can be readily tracked in circulation, holding immense potential as biomarkers for cancer treatment. An increasing number of studies focused on soluble immune checkpoints in cancer have emerged thanks to technological advancements. In this systematic review, we comprehensively summarized the recent studies on soluble immune checkpoints in human cancer risk prediction, outcome prediction, therapeutic applications, and potential molecular mechanisms, which demonstrated the promising future of soluble immune checkpoints in clinical applications. The clinical relevance of soluble immune checkpoints has been recognized in multiple cancers, yet the therapeutic applications and mechanisms remain obscure. Interpreting the impacts and mechanisms of soluble immune checkpoints could shed a light on the novel strategies of cancer screening, treatments, and outcome prediction.
- Open Access
Peripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study
Background: The immune checkpoint blockade remains obscure in osteosarcoma (OS). We aim to explore the clinical significance of soluble immune checkpoint (ICK)-related proteins in OS. Methods: We profiled 14 soluble ICK-related proteins (BTLA, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, CD28, CD80, CD137, CD27, and CTLA-4) in the plasma of 76 OS patients and matched controls. We evaluated the associations between the biomarkers and the risk of OS using unconditional multivariate logistic regression. The multivariate Cox model was utilized to develop the prediction model of OS. Immune subtypes were established from the identified biomarkers. Transcriptional data from GEO were analyzed to elucidate potential mechanisms. Results: We found that sTIM3, sCD137, sIDO, and sCTLA4 were significantly correlated with OS risk (all p < 0.05). sBTLA, sPDL2, and sCD27 were significantly associated with the risk of lung metastasis, whereas sBTLA and sTIM3 were associated with the risk of disease progression. We also established an immune subtype based on sBTLA, sPD1, sTIM3, and sPDL2. Patients in the sICK-type2 subtype had significantly decreased progression-free survival (PFS) and lung metastasis-free survival (LMFS) than those in the sICK-type1 subtype (log-rank p = 2.8 × 10−2, 1.7 × 10−2, respectively). Interestingly, we found that the trend of LMFS and PFS in the subtypes of corresponding ICK genes’ expression was opposite to the results in the blood (log-rank p = 2.6 × 10−4, 9.5 × 10−4, respectively). Conclusion: Four soluble ICK-related proteins were associated with the survival of OS patients. Soluble ICK-related proteins could be promising biomarkers for the outcomes and immunotherapy of OS patients, though more research is warranted.
Open AccessPeripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study
Background: The immune checkpoint blockade remains obscure in osteosarcoma (OS). We aim to explore the clinical significance of soluble immune checkpoint (ICK)-related proteins in OS. Methods: We profiled 14 soluble ICK-related proteins (BTLA, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, CD28, CD80, CD137, CD27, and CTLA-4) in the plasma of 76 OS patients and matched controls. We evaluated the associations between the biomarkers and the risk of OS using unconditional multivariate logistic regression. The multivariate Cox model was utilized to develop the prediction model of OS. Immune subtypes were established from the identified biomarkers. Transcriptional data from GEO were analyzed to elucidate potential mechanisms. Results: We found that sTIM3, sCD137, sIDO, and sCTLA4 were significantly correlated with OS risk (all p < 0.05). sBTLA, sPDL2, and sCD27 were significantly associated with the risk of lung metastasis, whereas sBTLA and sTIM3 were associated with the risk of disease progression. We also established an immune subtype based on sBTLA, sPD1, sTIM3, and sPDL2. Patients in the sICK-type2 subtype had significantly decreased progression-free survival (PFS) and lung metastasis-free survival (LMFS) than those in the sICK-type1 subtype (log-rank p = 2.8 × 10−2, 1.7 × 10−2, respectively). Interestingly, we found that the trend of LMFS and PFS in the subtypes of corresponding ICK genes’ expression was opposite to the results in the blood (log-rank p = 2.6 × 10−4, 9.5 × 10−4, respectively). Conclusion: Four soluble ICK-related proteins were associated with the survival of OS patients. Soluble ICK-related proteins could be promising biomarkers for the outcomes and immunotherapy of OS patients, though more research is warranted.
- Open Access
Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer
Background: Recent studies have revealed that neutrophils play a crucial role in cancer progression. This study aimed to explore the diagnostic value of neutrophil-related biomarkers for non-small-cell lung cancer (NSCLC). Methods: We initially assessed the associations between classic neutrophil-related biomarkers (neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil counts (NEU), absolute lymphocyte counts (LYM)) and NSCLC in 3942 cases and 6791 controls. Then, we measured 11 novel neutrophil-related biomarkers via Luminex Assays in 132 cases and 66 controls, individually matching on sex and age (±5 years), and evaluated their associations with NSCLC risk. We also developed the predictive models by sequentially adding variables of interest and assessed model improvement. Results: Interleukin-6 (IL-6) (odds ratio (OR) = 10.687, 95% confidence interval (CI): 3.875, 29.473) and Interleukin 1 Receptor Antagonist (IL-1RA) (OR = 8.113, 95% CI: 3.182, 20.689) shows strong associations with NSCLC risk after adjusting for body mass index, smoking status, NLR, and carcinoembryonic antigen. Adding the two identified biomarkers to the predictive model significantly elevated the model performance from an area under the receiver operating characteristic curve of 0.716 to 0.851 with a net reclassification improvement of 97.73%. Conclusions: IL-6 and IL-1RA were recognized as independent risk factors for NSCLC, improving the predictive performance of the model in identifying disease.
Open AccessCombining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer
Background: Recent studies have revealed that neutrophils play a crucial role in cancer progression. This study aimed to explore the diagnostic value of neutrophil-related biomarkers for non-small-cell lung cancer (NSCLC). Methods: We initially assessed the associations between classic neutrophil-related biomarkers (neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil counts (NEU), absolute lymphocyte counts (LYM)) and NSCLC in 3942 cases and 6791 controls. Then, we measured 11 novel neutrophil-related biomarkers via Luminex Assays in 132 cases and 66 controls, individually matching on sex and age (±5 years), and evaluated their associations with NSCLC risk. We also developed the predictive models by sequentially adding variables of interest and assessed model improvement. Results: Interleukin-6 (IL-6) (odds ratio (OR) = 10.687, 95% confidence interval (CI): 3.875, 29.473) and Interleukin 1 Receptor Antagonist (IL-1RA) (OR = 8.113, 95% CI: 3.182, 20.689) shows strong associations with NSCLC risk after adjusting for body mass index, smoking status, NLR, and carcinoembryonic antigen. Adding the two identified biomarkers to the predictive model significantly elevated the model performance from an area under the receiver operating characteristic curve of 0.716 to 0.851 with a net reclassification improvement of 97.73%. Conclusions: IL-6 and IL-1RA were recognized as independent risk factors for NSCLC, improving the predictive performance of the model in identifying disease.